Trans-Pa­cif­ic pow­er play­er Ever­est jumps on mR­NA vac­cine deal with Prov­i­dence, pay­ing $100M up­front to tap plat­form play

Ever­est is jump­ing aboard the Covid-19 mR­NA vac­cine train.

While Chi­na has used oth­er vac­cine tech­nolo­gies to vac­ci­nate its pop­u­la­tion, com­pa­nies are start­ing to ex­plore the use of mR­NA vac­cines in Asian mar­kets. Ever­est is now the lat­est com­pa­ny to fo­cus on the Chi­nese mar­ket in a deal with Cana­di­an biotech Prov­i­dence Ther­a­peu­tics.

As part of the deal, Prov­i­dence will get $100 mil­lion up­front in cash, com­bined with an ad­di­tion­al up to $400 mil­lion in prof­it-shar­ing on the Covid-19 vac­cines and mile­stone pay­ments on col­lab­o­ra­tive and ad­di­tion­al prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER